Zacks Investment Research upgraded shares of Fluidigm (NASDAQ:FLDM) from a sell rating to a hold rating in a report issued on Thursday, September 20th.
According to Zacks, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California. “
Other analysts have also recently issued research reports about the company. ValuEngine raised Fluidigm from a strong sell rating to a sell rating in a research report on Wednesday, May 23rd. BidaskClub raised Fluidigm from a hold rating to a buy rating in a research report on Wednesday, September 12th.
NASDAQ:FLDM traded up $0.62 during midday trading on Thursday, hitting $7.86. The stock had a trading volume of 255,400 shares, compared to its average volume of 184,684. Fluidigm has a one year low of $4.43 and a one year high of $8.62. The stock has a market cap of $293.33 million, a P/E ratio of -6.61 and a beta of 3.44. The company has a quick ratio of 1.64, a current ratio of 2.05 and a debt-to-equity ratio of 4.79.
Fluidigm (NASDAQ:FLDM) last announced its earnings results on Thursday, August 2nd. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.03). The company had revenue of $26.43 million for the quarter, compared to the consensus estimate of $26.30 million. Fluidigm had a negative net margin of 53.65% and a negative return on equity of 104.75%. On average, sell-side analysts anticipate that Fluidigm will post -0.99 EPS for the current fiscal year.
In related news, insider Levin Capital Strategies, L.P. acquired 25,500 shares of Fluidigm stock in a transaction on Wednesday, August 15th. The stock was acquired at an average price of $6.78 per share, for a total transaction of $172,890.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have acquired a total of 86,459 shares of company stock valued at $594,041 in the last quarter. Company insiders own 2.20% of the company’s stock.
Several large investors have recently bought and sold shares of FLDM. Engineers Gate Manager LP acquired a new stake in shares of Fluidigm during the 1st quarter valued at about $128,000. LMR Partners LLP acquired a new stake in shares of Fluidigm during the 2nd quarter valued at about $144,000. Trexquant Investment LP acquired a new stake in shares of Fluidigm during the 1st quarter valued at about $165,000. Wells Fargo & Company MN grew its position in shares of Fluidigm by 64.8% during the 1st quarter. Wells Fargo & Company MN now owns 28,945 shares of the medical research company’s stock valued at $169,000 after acquiring an additional 11,377 shares during the period. Finally, New York State Common Retirement Fund boosted its holdings in Fluidigm by 47.9% in the 1st quarter. New York State Common Retirement Fund now owns 38,900 shares of the medical research company’s stock worth $227,000 after buying an additional 12,600 shares during the last quarter. Hedge funds and other institutional investors own 96.73% of the company’s stock.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
Read More: Return on Equity (ROE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.